Cynata Therapeutics Completes Patient Enrollment in Clinical Trial for aGvHD Treatment Cynata Therapeutics has completed enrollment in its Phase 2 trial of CYP-001 for acute graft versus host disease, an urgent unmet need in treatment.

Cynata Therapeutics Completes Patient Enrollment in Clinical Trial for aGvHD Treatment #Australia #Melbourne #Cynata_Therapeutics #CYP-001 #aGvHD

Cynata Therapeutics' CYP-006TK Shows Promise in Healing Diabetic Foot Ulcers Cynata Therapeutics Limited's Phase 1 trial reveals CYP-006TK as a safe and effective treatment for diabetic foot ulcers. This breakthrough could revolutionize care.

Cynata Therapeutics' CYP-006TK Shows Promise in Healing Diabetic Foot Ulcers #Australia #Melbourne #Cynata_Therapeutics #CYP-006TK #Diabetic_Foot_Ulcers